DOT Summary of Changes
The Department of Transportation (DOT) published a final rule in the Federal Register (82 FR 52229).
You can find a copy of the final rule on ODAPC’s web site www.transportation.gov/odapc/frpubs.
What does this mean for laboratories?
Effective January 1, 2018, laboratories have added four semi-synthetic opioids: hydrocodone, oxycodone, hydromorphone; oxymorphone to your DOT testing panel.
Beginning July 1 2018, SAMSHA laboratories will require that all DOT urine specimens be accompanied by the new federal chain of custody and control form (CCF)
What does this mean for employees?
Employees will be tested for four semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone). Some common names for these semi-synthetic opioids include OxyContin®, Percodan®, Percocet®, Vicodin®, Lortab®, Norco®, Dilaudid® and Exalgo®. In addition, employees will no longer be tested for MDEA.
What does this mean for employers?
As a C/TPA we always advise companies to educate employees about the opioid epidemic; communicate the risk factors for opioid abuse and stress the importance of responsible prescription use. It is also important to provide support and safe return to work for injured employees, and communicate treatment options, if needed.
Employers can also remove the sub-categories of drugs and just refer to ’49 CFR part 40.’ If cut-off levels are listed in current policies, employers must update those cut-off levels or refer more generally to the applicable cutoff values stated in 49 CFR part 40.
You should notify your employees of these new changes immediately.
NOTE: This document informally summarizes some of the important effects of the rule, but it is not a substitute for the rule and should not be relied upon to determine legal compliance with the rule. CCM encourages affected entities, including employers and service agents, to review the final rule. www.transportation.gov/odapc/frpubs.
Click on a question to see the answer.